Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, and the 5‐year survival rate was only 7.7%. To improve prognosis, a screening biomarker for early diagnosis of pancreatic cancer is in urgent need. Long non‐coding RNA (lncRNA) expression profiles as potential cancer prognostic biomarkers play critical roles in development of tumorigenesis and metastasis of cancer. However, lncRNA signatures in predicting the survival of a patient with PDAC remain unknown. In the current study, we try to identify potential lncRNA biomarkers and their prognostic values in PDAC. LncRNAs expression profiles and corresponding clinical information for 182 cases with PDAC were acquired from The Cancer Genome Atlas (TCGA). A total of 14 470 lncRNA were identified in the cohort, and 175 PDAC patients had clinical variables. We obtained 108 differential expressed lncRNA via R packages. Univariate and multivariate Cox proportional hazards regression, lasso regression was performed to screen the potential prognostic lncRNA. Five lncRNAs have been recognized to significantly correlate with OS. We established a linear prognostic model of five lncRNA (C9orf139, MIR600HG, RP5‐965G21.4, RP11‐436K8.1, and CTC‐327F10.4) and divided patients into high‐ and low‐risk group according to the prognostic index. The five lncRNAs played independent prognostic biomarkers of OS of PDAC patients and the AUC of the ROC curve for the five lncRNAs signatures prediction 5‐year survival was 0.742. In addition, targeted genes of MIR600HG, C9orf139, and CTC‐327F10.4 were explored and functional enrichment was also conducted. These results suggested that this five‐lncRNAs signature could act as potential prognostic biomarkers in the prediction of PDAC patient's survival.

Integrated analysis of long noncoding RNA associated‐competing endogenous RNA as prognostic biomarkers in clear cell renal carcinoma

“…The lncRNA FMO6P and PRR26 were identified to construct a risk score to predict the prognostic value in lung cancer . In pancreatic ductal adenocarcinoma, a 5‐lncRNA signature (C9orf139, MIR600HG, RP5‐965G21.4, RP11‐436K8.1 and CTC‐327F10.4) could be used to make prognoses for patients . In ER‐positive breast cancer, a 6‐lncRNA (HAGLR, STK4‐AS1, DLEU7‐AS1, LINC00957, LINC01614 and ITPR1‐AS1) signature was a potential prognostic marker for survival prediction .…”

“…and CTC-327F10.4) could be used to make prognoses for patients. 36 In ER-positive breast cancer, a 6-lncRNA (HAGLR, STK4-AS1, DLEU7-AS1, LINC00957, LINC01614 and ITPR1-AS1) signature was a potential prognostic marker for survival prediction. 37 In esophageal squamous cell cancer, a 3-lncRNA signature could predict overall survival.…”

Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma

“…Nowadays, a large number of high‐throughput sequencing datasets are shared in public databases for researchers to have open access to downloads, especially The Cancer Genome Atlas (TCGA) database from National Cancer Institute as well as National Human Genome Research Institute . Previous studies have used TCGA data to identify pancreatic cancer‐related lncRNA molecular markers and to screen a number of lncRNAs associated with pancreatic cancer prognosis . However, since TCGA database contains a large amount of genome‐wide RNA sequencing dataset, and previous studies have failed to fully analyze these data.…”

“…5 Previous studies have used TCGA data to identify pancreatic cancer-related lncRNA molecular markers and to screen a number of lncRNAs associated with pancreatic cancer prognosis. 6,7 However, since TCGA database contains a large amount of genome-wide RNA sequencing dataset, and previous studies have failed to fully analyze these data. Therefore, the lncRNA markers related to the prognosis of pancreatic cancer from TCGA cohort need to be further explored.…”

Identificação e anotação funcional de novos transcritos com expressão alterada no câncer pancreático

“…Dois trabalhos utilizaram microarranjos de cDNA para analisar amostras T/N identificando perfis de expressão de lncRNAs associados com malignidade e metástase (Tahira et al 2011;Fu et al 2016) . Recentemente, Song e colaboradores exploraram dados de expressão de 178 amostras de PDAC e apenas 4 de tecido não tumoral de pâncreas e encontraram 5 lncRNAs com potencial como marcador prognóstico ( C9orf139 , MIR600HG , RP5-965G21.4 , RP11-436K8.1 , e CTC-327F10.4 ) (Song et al 2018) . O grupo de Mao et al foi o único que utilizou amostras pareadas de tecidos tumorais e normais adjacentes (n=10) (Mao et al 2017) .…”